| Cas No.: | 1223002-54-7 |
| Synonyms: | QL-IX-55,QL IX 55,QLIX55 |
| SMILES: | NC1=NC=C(C2=CC=C(N=CC(C=C3)=C4N(C5=CC(C(F)(F)F)=C(F)C=C5)C3=O)C4=C2)C=C1 |
| Formula: | C24H14F4N4O |
| M.Wt: | 450.39 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively. IC50 value: 50/50/10-50 nM (Human mTORC1/Yeast The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiased selection strategies. QL-IX-55 is capable of potently inhibiting both TOR complex 1 and 2 (TORC1 and TORC2) as demonstrated by biochem. IP kinase assays (IC50 <50 nM) and cellular assays for inhibition of substrate YPK1 phosphorylation. In contrast to rapamycin, QL-IX-55 is capable of inhibiting TORC2-dependent transcription, which suggests that this compd. will be a powerful probe to dissect the Tor2/TORC2-related signaling pathway in yeast.. For the detailed information of QL-IX-55, the solubility of QL-IX-55 in water, the solubility of QL-IX-55 in DMSO, the solubility of QL-IX-55 in PBS buffer, the animal experiment (test) of QL-IX-55, the cell expriment (test) of QL-IX-55, the in vivo, in vitro and clinical trial test of QL-IX-55, the EC50, IC50,and affinity,of QL-IX-55, Please contact DC Chemicals. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
